Life Sciences
Earnings reports: Fathom Holdings, Asensus Surgical, VTv Therapeutics
Three more public companies have updated their earnings. Here’s the latest from Fathom Holdings, Asensus Surgical and VTv Therapeutics.
The post Earnings…
Three more public companies have updated their earnings. Here’s the latest:
Fathom Holdings
CARY — Fathom Holdings Inc. (FTHM) on Wednesday reported a loss of $5.7 million in its first quarter.
On a per-share basis, the Cary, North Carolina-based company said it had a loss of 36 cents.
The company posted revenue of $77.5 million in the period.
For the current quarter ending in June, Fathom Holdings said it expects revenue in the range of $88 million to $90 million.
Asensus Surgical
DURHAM — Asensus Surgical, Inc. (ASXC) on Thursday reported a loss of $22.2 million in its first quarter.
On a per-share basis, the Durham, North Carolina-based company said it had a loss of 9 cents.
The maker of surgical robots and medical instruments posted revenue of $976,000 in the period.
In the final minutes of trading on Thursday, the company’s shares hit 63 cents. A year ago, they were trading at 37 cents.
VTv Therapeutics
HIGH POINT — VTv Therapeutics Inc. (VTVT) on Thursday reported a loss of $4.5 million in its first quarter.
The High Point, North Carolina-based company said it had a loss of 6 cents per share.
The post Earnings reports: Fathom Holdings, Asensus Surgical, VTv Therapeutics first appeared on WRAL TechWire.
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….